When does Stelara’s patent or exclusivity expire?
The “expiry date” for Stelara can mean different things—most commonly a patent expiration date or an FDA exclusivity date (which can extend market protection even after a patent ends). The exact date depends on the specific right (patent vs. exclusivity) and the country.
DrugPatentWatch.com tracks these protections for branded drugs, including Stelara, and is a practical place to check the latest status and dates: DrugPatentWatch – Stelara.
How long does Stelara keep competitors off the market?
Stelara’s market protection typically comes from a mix of:
- Patents covering the product and/or manufacturing or formulation.
- Exclusivity periods granted by the FDA that can delay generic or biosimilar competition even if some patents expire.
Because these protections can differ by jurisdiction and by product details (including strength and indication), you’ll usually need to look up the specific listed protections for Stelara rather than rely on one single “expiry date.” DrugPatentWatch – Stelara is designed for that purpose.
Is there more than one “expiry date” for Stelara (patents vs. biosimilar pathways)?
Yes. Stelara is an injectable biologic, so the relevant “next competitors” are usually biosimilars. Those timelines can differ based on:
- Which patents are still in force.
- Whether exclusivity still applies.
- How long related litigation and regulatory review take.
So the date a competitor can launch may not match the date a specific patent expires.
What I need to give you a precise date
If you want the exact “Stelara expiry date” you’re looking for, tell me which one you mean:
1) Patent expiration (and which patent/family, if you have it), or
2) FDA exclusivity expiration, or
3) The earliest date a biosimilar could enter (launch date), or
4) The country (US, EU, etc.).
Share any details you have (e.g., “US patent expiry” or “biosimilar entry date”), and I can narrow it down.
Sources
- DrugPatentWatch – Stelara